Clinical outcome of high-dose-rate interstitial brachytherapy in vulvar cancer: A single institutional experience

详细信息    查看全文

• 作者：Umesh Mahantshetty¹ ; ^{drumeshm@gmail.com} ; Pushpa Naga¹ ; Reena Engineer¹ ; Supriya Sastri¹ ; Yogesh Ghadi² ; Udita Upreti² ; Vijaya Somesan² ; Sudarshan Kadam² ; Satish Kohle² ; Deepak Deshpande² ; Shyam Kishore Shrivastava¹
• 关键词：Vulvar cancer ; Interstitial brachytherapy ; HDR ; Clinical outcome ; Toxicity
• 刊名：Brachytherapy
• 出版年：2017
• 出版时间：January-February 2017
• 年：2017
• 卷：16
• 期：1
• 页码：153-160
• 全文大小：1510 K
• 卷排序：16

文摘

With an aim to evaluate and report high dose date interstitial brachytherapy (HDR-ISBT) in vulvar cancers, we undertook this retrospective analysis.Methods and MaterialsHistologically proven vulvar cancers treated with HDR-ISBT between 2001 and 2016 were analyzed. Radiotherapy details, clinical outcome in terms of local control rates, survivals, and toxicities were evaluated.ResultsA total of 38 patients received HDR-ISBT, with definitive radiation in 29 (76.3%), adjuvant postoperative in six (15.8%) and salvage radiation in three (7.9%) patients. Of them, 29 patients received brachytherapy boost and nine patients ISBT alone. BT procedure included freehand plastic tube technique in 23 (single [n = 5] or multiple plane [n = 18]), 13 patients with template based and two patients combined approach. Patients with brachytherapy alone received median EQD2 of 38.4 Gy10 (35.5–46.7 Gy10), as boost received median 23.3 Gy10 (13–37.3 Gy10). At 3-month post-treatment response evaluation, 30 patients achieved clinically complete response, two patients partial response and six maintained postoperative status. With a median follow-up of 30 months, 29 (76.3%) were disease free, and 9 (23.7%) patients had relapsed disease with four patients expired due to disease and two died of other causes. The 5-year overall survival, disease free survival, and local control rates were 82%, 51%, and 77%, respectively.ConclusionsHDR-ISBT in vulvar cancer is a feasible and a viable option with acceptable and comparable outcomes.